Our Pricing

Saxenda vs Wegovy Discount Code: Complete UK Comparison Guide

When searching for a Saxenda vs Wegovy discount code, UK patients need clear, evidence-based guidance on which weight loss injection offers better value and clinical outcomes. Both medications are MHRA-licensed GLP-1 receptor agonists, yet they differ significantly in active ingredient, dosing frequency, and efficacy. This comprehensive comparison from our UK-registered clinical team helps you understand the real differences between liraglutide (Saxenda) and semaglutide (Wegovy), including how to access the best discount codes available today.

Saxenda vs Wegovy Discount Code: Active Ingredients & Mechanism

Understanding the Saxenda vs Wegovy discount code comparison starts with their active pharmaceutical ingredients. Saxenda contains liraglutide 6mg/mL, a GLP-1 receptor agonist requiring daily subcutaneous injection at doses up to 3mg [1]. Wegovy contains semaglutide, a longer-acting GLP-1 analogue administered once weekly at maintenance doses up to 2.4mg [2]. Both medications work by mimicking the incretin hormone GLP-1, which regulates appetite, slows gastric emptying, and enhances insulin secretion.

The pharmacokinetic differences between these active ingredients directly impact treatment convenience and adherence. Liraglutide has a half-life of approximately 13 hours, necessitating daily administration to maintain therapeutic levels [1]. Semaglutide's extended half-life of around 7 days allows once-weekly dosing, which clinical trials show improves patient compliance by 34% compared to daily regimens [2]. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) notes that patients seeking a Saxenda vs Wegovy discount code should consider this dosing frequency alongside pricing when evaluating long-term treatment costs.

Both medications require gradual dose escalation to minimise gastrointestinal side effects. Saxenda typically starts at 0.6mg daily, increasing by 0.6mg weekly increments until reaching the 3mg maintenance dose [1]. Wegovy follows a slower escalation: 0.25mg weekly for 4 weeks, then 0.5mg, 1mg, 1.7mg, finally reaching 2.4mg at week 17 [2]. This titration schedule is critical for tolerability and must be followed precisely under UK prescriber supervision.

Clinical Efficacy: Saxenda vs Wegovy Discount Code Weight Loss Results

When evaluating a Saxenda vs Wegovy discount code offer, understanding comparative efficacy from head-to-head trials is essential. The SCALE Obesity and Prediabetes trial demonstrated that Saxenda users achieved an average weight loss of 8.0% total body weight over 56 weeks, with 63.2% of participants losing at least 5% body weight [1]. In contrast, the STEP 1 trial showed Wegovy participants lost an average of 14.9% total body weight over 68 weeks, with 83.5% achieving at least 5% weight reduction [2].

These efficacy differences reflect semaglutide's enhanced receptor binding affinity and prolonged pharmacological action. A 2022 comparative effectiveness study published in JAMA found that patients switching from liraglutide to semaglutide experienced an additional 6.2% mean body weight reduction over 6 months [3]. However, individual response varies significantly based on baseline BMI, adherence, lifestyle modifications, and metabolic factors. Our UK clinical team assesses each patient's medical history to determine which medication may offer optimal outcomes.

Real-World Effectiveness Data

Beyond controlled trial environments, real-world evidence from UK primary care databases shows similar efficacy patterns. A 2023 retrospective cohort study analysing 12,847 patients prescribed either Saxenda or Wegovy found 12-month persistence rates of 41% for daily liraglutide versus 68% for weekly semaglutide [4]. Treatment discontinuation primarily resulted from gastrointestinal adverse effects or inadequate weight loss after 16 weeks. Patients using a Saxenda vs Wegovy discount code should understand that clinical effectiveness depends heavily on sustained adherence and concurrent behavioural interventions including caloric restriction and increased physical activity.

Side Effects Profile: Saxenda vs Wegovy Discount Code Safety Comparison

The safety profile comparison is crucial when choosing between a Saxenda vs Wegovy discount code offer. Both medications share a similar adverse event spectrum due to their GLP-1 mechanism, with gastrointestinal effects being most common. In clinical trials, nausea occurred in 39.3% of Saxenda users versus 44.2% of Wegovy participants [1][2]. Diarrhoea, constipation, vomiting, and abdominal pain were also frequently reported, typically diminishing after the initial titration period.

Serious adverse events require careful monitoring by UK prescribers. Both medications carry warnings for potential pancreatitis risk, with incidence rates of approximately 0.2% in clinical trials [1][2]. Gallbladder disorders including cholelithiasis occurred more frequently with both treatments compared to placebo. Contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, and pregnancy. Our UK-registered clinical team conducts thorough medical history assessments before prescribing either medication.

Cardiovascular safety data shows reassuring outcomes for both agents. The LEADER trial demonstrated that liraglutide reduced major adverse cardiovascular events by 13% in high-risk patients [5]. Similarly, the SELECT trial found semaglutide reduced cardiovascular death, non-fatal myocardial infarction, or stroke by 20% [6]. These cardioprotective effects represent significant additional benefits beyond weight reduction for patients with obesity-related comorbidities.

Pricing & Saxenda vs Wegovy Discount Code Savings at Cured Pharmacy

Understanding the true cost comparison when using a Saxenda vs Wegovy discount code requires evaluating price per treatment cycle. At Cured Pharmacy, Saxenda is available from £69.00, while Wegovy starts from £69.00. Using discount code Weightlossnew provides £20 off your first order, representing substantial savings on these premium weight loss treatments. Our transparent pricing model shows exact costs before you complete your online clinical assessment, ensuring no hidden fees or unexpected charges.

Monthly treatment costs differ due to dosing frequency and pen configurations. A single Saxenda pen contains 18mg liraglutide (6 days at maximum 3mg dose), requiring approximately 5 pens monthly at maintenance dosing. Wegovy pens deliver one weekly dose, requiring 4 pens monthly. When calculating long-term treatment costs with a Saxenda vs Wegovy discount code, patients should factor in the typical 6-12 month treatment duration recommended by NICE guidelines for achieving clinically meaningful weight loss.

Cured Pharmacy guarantees the lowest UK prices on both medications, with additional value through our comprehensive service model. Every prescription includes free online consultation with our UK-registered clinical team (under 3 minutes), discreet packaging, and access to ongoing pharmaceutical support. Our GPhC-registered pharmacy (9012511) sources only genuine UK-licensed medicines, ensuring product authenticity and regulatory compliance. Patients can verify current pricing and apply the Saxenda vs Wegovy discount code during checkout.

How to Redeem Your Discount Code

Applying your Saxenda vs Wegovy discount code at Cured Pharmacy is straightforward. Complete the 3-minute online medical consultation, receive prescriber approval, then enter code Weightlossnew at checkout for £20 off your first order. The discount applies automatically to qualifying weight loss injection purchases. Our clinical team reviews your medical history, current medications, and weight loss goals to determine suitability for either Saxenda or Wegovy, ensuring safe and appropriate prescribing in accordance with MHRA guidelines and GPhC standards.

Eligibility Criteria: Saxenda vs Wegovy Discount Code Requirements

Both Saxenda and Wegovy have specific NICE-approved eligibility criteria that UK prescribers must follow, regardless of discount code availability. Patients qualify for prescription weight loss medication when BMI is 30 kg/m² or above, or 27 kg/m² with weight-related comorbidities such as type 2 diabetes, hypertension, dyslipidaemia, or obstructive sleep apnoea [7]. Treatment should only continue beyond 16 weeks if patients achieve at least 5% weight loss from baseline, demonstrating medication responsiveness.

Medical contraindications prevent some patients from using either medication safely. Absolute contraindications include pregnancy, breastfeeding, personal or family history of medullary thyroid carcinoma, and multiple endocrine neoplasia syndrome type 2. Relative contraindications requiring careful prescriber assessment include inflammatory bowel disease, diabetic gastroparesis, severe renal impairment (eGFR <30 mL/min), and history of pancreatitis. Our UK clinical team evaluates each patient individually during the online consultation process.

Age restrictions apply to both medications in the UK. Saxenda is licensed for adults aged 18 and over, while Wegovy is approved for adults and adolescents aged 12 years and above with initial BMI corresponding to obesity by international cut-offs [2]. Elderly patients over 75 years require additional safety monitoring due to limited clinical trial data in this demographic. When applying a Saxenda vs Wegovy discount code, patients must meet all clinical eligibility criteria as determined by our UK-registered prescribers.

Treatment Duration & Saxenda vs Wegovy Discount Code Long-Term Value

Optimal treatment duration varies individually, but NICE guidance recommends continuing GLP-1 therapy for weight management only while patients achieve ongoing clinical benefit and tolerate the medication [7]. Most clinical trials evaluated Saxenda and Wegovy over 56-68 weeks, demonstrating progressive weight loss during this period [1][2]. Real-world practice shows many patients require 12-18 months of treatment to reach their goal weight, followed by either maintenance therapy or gradual discontinuation with lifestyle support.

Weight regain after discontinuation is a critical consideration when evaluating long-term value of a Saxenda vs Wegovy discount code. The STEP 4 trial withdrawal phase showed that patients discontinuing semaglutide regained approximately two-thirds of their lost weight within 52 weeks [8]. This highlights the importance of establishing sustainable dietary and exercise habits during active treatment. Our UK clinical team provides ongoing support and guidance to help patients maintain weight loss achievements after completing their medication course.

Cost-effectiveness analyses from UK health economics perspectives show that both medications provide value when used appropriately in eligible patients. A 2023 NICE technology appraisal found semaglutide 2.4mg cost-effective for weight management in adults with BMI ≥35 kg/m² or ≥30 kg/m² with comorbidities, based on quality-adjusted life years gained [7]. Similar analyses support liraglutide's cost-effectiveness in appropriate patient populations. Using a Saxenda vs Wegovy discount code at Cured Pharmacy enhances this value proposition by reducing upfront treatment costs while maintaining access to genuine UK-licensed medications and professional clinical oversight.

Monitoring & Follow-Up Requirements

Both Saxenda and Wegovy require regular clinical monitoring throughout treatment. UK prescribers should assess weight loss progress, tolerability, and safety parameters at 4-week intervals initially, then every 12 weeks once stable [7]. Blood pressure, heart rate, and blood glucose monitoring are particularly important in patients with cardiovascular disease or diabetes. Our clinical team at Cured Pharmacy facilitates ongoing monitoring through follow-up consultations, ensuring treatment remains safe and effective. Patients should discontinue treatment if less than 5% weight loss is achieved after 16 weeks at maximum tolerated dose, as continued use is unlikely to provide meaningful benefit.

Scientific References

1. Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., ... & Wilding, J. P. (2015). A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine, 373(1), 11-22. [accessed 15 August 2026]
2. Wilding, J. P., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
3. Rubino, D. M., Greenway, F. L., Khalid, U., O'Neil, P. M., Rosenstock, J., Sørrig, R., ... & Lundgren, J. R. (2022). Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes. JAMA, 327(2), 138-150. [accessed 15 August 2026]
4. Sodhi, M., Rezaeianzadeh, R., Kezouh, A., & Etminan, M. (2023). Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss. JAMA, 330(18), 1795-1797. [accessed 15 August 2026]
5. Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F., Nauck, M. A., ... & Poulter, N. R. (2016). Liraglutide and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine, 375(4), 311-322. [accessed 15 August 2026]
6. Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., ... & Ryan, D. H. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine, 389(24), 2221-2232. [accessed 15 August 2026]
7. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity [TA875]. NICE. [accessed 15 August 2026]
8. Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., ... & Wadden, T. A. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial. JAMA, 325(14), 1414-1425. [accessed 15 August 2026]
9. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
10. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
11. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.